ACXP

$4.88

Market ClosedAs of Mar 17, 8:00 PM UTC

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Zacks
Mar 17, 2026

Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Associated Press Finance
Mar 11, 2026

BC-Most Active Stocks

Elong Power Holding Ltd. 79,546,080 0.0559

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Feb 24, 2026

Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is one of the best up and coming penny stocks to buy. On February 2, Acurx Pharmaceuticals announced that the United States Patent and Trademark Office granted a new patent, US 12,534,470, covering its DNA Polymerase IIIC inhibitors. This patent includes compositions-of-matter, methods of use, and pharmaceutical compositions, reinforcing the company’s […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 21, 2026

Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term

With the business potentially at an important milestone, we thought we'd take a closer look at Acurx Pharmaceuticals...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Jan 6, 2026

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.